Sugi Predict

Sugi Predict / Compounds / SCHEMBL836449

SCHEMBL836449

SCHEMBL836449

O=Cc1ccc2c(c1O)CCC2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTRC Q99895 1/20 0.47
▸ ERN1 O75460 4/20 0.39
▸ BCL2L1 Q07817 1/20 0.38
▸ BAD Q92934 1/20 0.38
▸ PARP1 P09874 1/20 0.36
▸ NQO1 P15559 3/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ TLR2 O60603 1/20 0.34
▸ TLR1 Q15399 1/20 0.34
▸ TLR6 Q9Y2C9 1/20 0.34
▸ GRIA1 P42261 1/20 0.34
▸ GRIA2 P42262 1/20 0.34
▸ GRIA3 P42263 1/20 0.34
▸ GRIA4 P48058 1/20 0.34
▸ TRIM24 O15164 1/20 0.33
▸ TRIM33 Q9UPN9 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29442687 1.00 CTRC (0.47) CTRCERN1BCL2L1BADPARP1
SCHEMBL6682317 0.96 CTRC (0.50) CTRCERN1BCL2L1BADNQO1
SCHEMBL8830529 0.74 CTRC (0.45) CTRCBCL2L1BADNQO1MEN1
SCHEMBL8830527 0.74 CTRC (0.45) CTRCBCL2L1BADNQO1MEN1
SCHEMBL30777448 0.73 BCL2L1 (0.42) ERN1BCL2L1BADPARP1NQO1
SCHEMBL837149 0.73 KMT2A (0.56) ERN1PARP1MEN1KMT2ATRIM24
SCHEMBL9668382 0.73 CTRC (0.44) CTRCBCL2L1BADNQO1GRIA1
SCHEMBL1535927 0.73 BCL2L1 (0.50) BCL2L1BAD
SCHEMBL30777455 0.72 BCL2L1 (0.45) ERN1BCL2L1BADMEN1KMT2A
SCHEMBL1616679 0.72 BCL2L1 (0.45) ERN1BCL2L1BADMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559504-B2 Benzotriazole derivative UBE CORPORATION (JP) 2026-02-24 — — US disclosed
EP-3978073-B1 1H-BENZO[D][1,2,3]TRIAZOLE DERIVATIVES AS KEAP1 INHIBITORS FOR THE TREATMENT OF RENAL DISEASES UBE CORP (JP) 2025-10-15 — — EP disclosed
CN-112105610-B Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation 朱比连特普罗德尔有限责任公司 2024-01-26 — — CN disclosed
US-11529341-B2 Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation Jubilant Prodel LLC 2022-12-20 — — US disclosed
US-11529341-B2 Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation Jubilant Prodel LLC 2022-12-20 — — US disclosed
US-20220259223-A1 BENZOTRIAZOLE DERIVATIVE UBE INDUSTRIES, LTD. (JP) 2022-08-18 — — US disclosed
US-20220259223-A1 BENZOTRIAZOLE DERIVATIVE UBE INDUSTRIES, LTD. (JP) 2022-08-18 — — US disclosed
EP-3978073-A1 BENZOTRIAZOLE DERIVATIVE Ube Industries, Ltd. (JP) 2022-04-06 — — EP disclosed
CN-114174289-A Benzotriazole derivatives 宇部兴产株式会社 2022-03-11 — — CN disclosed
US-20210015810-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION Jubilant Prodel LLC 2021-01-21 — — US disclosed
WO-2016001834-A1 TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-07 — — WO disclosed
CN-101772487-B Thyroid compounds TORRENT PHARMACEUTICALS LTD 2014-01-22 — — CN disclosed
US-8378118-B2 Pyrazole-based thyroid receptor compounds TORRENT PHARMACEUTICALS LTD. (IN) 2013-02-19 — — US disclosed
US-20120202816-A1 NOVEL COMPOUNDS TORRENT PHARMACEUTICALS, LTD. (IN) 2012-08-09 — — US disclosed
US-8143424-B2 Thyroid like compounds TORRENT PHARMACEUTICALS LTD. (IN) 2012-03-27 — — US disclosed
EP-2061766-B1 NOVEL COMPOUNDS TORRENT PHARMACEUTICALS LTD (IN) 2010-08-18 — — EP disclosed
CN-101772487-A Novel compound TORRENT PHARMACEUTICALS LTD 2010-07-07 — — CN disclosed
US-20100168110-A1 Novel Compounds TORRENT PHARMACEUTICALS LTD. (IN) 2010-07-01 — — US disclosed
EP-2061766-A2 NOVEL COMPOUNDS Torrent Pharmaceuticals Ltd (IN) 2009-05-27 — — EP disclosed
WO-2008149379-A2 NOVEL COMPOUNDS TORRENT PHARMACEUTICALS LTD. (IN) 2008-12-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559504-B2 Benzotriazole derivative KEAP1, NFE2L2, NCOR1 CTRC 4130/4885ERN1 3021/4885BCL2L1 2565/4885
US-20120202816-A1 NOVEL COMPOUNDS TSHR, THRB, GPR119 CTRC 4365/4885ERN1 3029/4885BCL2L1 3358/4885
US-20210015810-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION CD274, PDCD1, PDCD1LG2 CTRC 3556/4885ERN1 2506/4885BCL2L1 349/4885
US-20220259223-A1 BENZOTRIAZOLE DERIVATIVE KEAP1, NFE2L2, BACH1 CTRC 4573/4885ERN1 3201/4885BCL2L1 2989/4885
US-20100168110-A1 Novel Compounds TSHR, THRB, GPR119 CTRC 4365/4885ERN1 3029/4885BCL2L1 3358/4885
US-11529341-B2 Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation CD274, PDCD1, PDCD1LG2 CTRC 3556/4885ERN1 2506/4885BCL2L1 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.